Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586306 | 0.82 | EPHX2 (0.49) | EPHX2CHRNA7CYP2C9CYP2J2NAMPT | |
| SCHEMBL9596961 | 0.81 | EPHX2 (0.48) | EPHX2CHRNA7CYP2C9CYP2J2NAMPT | |
| SCHEMBL6585239 | 0.80 | EPHX2 (0.47) | EPHX2CHRNA7CYP2C9CYP2J2 | |
| SCHEMBL6586275 | 0.80 | EPHX2 (0.47) | EPHX2CHRNA7CYP2C9CYP2J2 | |
| SCHEMBL6585234 | 0.80 | EPHX2 (0.47) | EPHX2CHRNA7CYP2C9CYP2J2 | |
| SCHEMBL9450755 | 0.80 | EPHX2 (0.45) | EPHX2 | |
| SCHEMBL9596858 | 0.79 | EPHX2 (0.48) | EPHX2CHRNA7CYP2C9CYP2J2 | |
| SCHEMBL5220841 | 0.75 | RBP4 (0.43) | EPHX2RBP4NAMPT | |
| SCHEMBL17729479 | 0.73 | EPHX2 (0.46) | EPHX2 | |
| SCHEMBL9450741 | 0.73 | EPHX2 (0.49) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1049671-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RES LTD (GB) | 2004-04-21 | — | — | EP | claimed |
| US-6514961-B1 | Such as anxiety and all forms of epilepsy, particularly in humans | VERNALIS RESEARCH LIMITED (GB) | 2003-02-04 | — | — | US | claimed |
| EP-1196166-A1 | AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2002-04-17 | — | — | EP | claimed |
| WO-2001007043-A1 | AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | claimed |
| EP-1049671-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037614-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | claimed |
| EP-1049671-B1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RES LTD (GB) | 2004-04-21 | — | — | EP | disclosed |
| US-6514961-B1 | Such as anxiety and all forms of epilepsy, particularly in humans | VERNALIS RESEARCH LIMITED (GB) | 2003-02-04 | — | — | US | disclosed |
| EP-1196166-A1 | AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007043-A1 | AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-1049671-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037614-A1 | AZETIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 1999-07-29 | — | — | WO | disclosed |